Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
ABC News

How Do Ductal Carcinoma and Lobular Carcinoma In Situ Differ?

Dr. Schwartz answers the question: 'Difference between in situ breast cancers?' — -- Question: What is the difference between ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS)?
Yahoo

What is ductal carcinoma in situ? Everything to know about the cancer affecting Danielle Fishel

Actress Danielle Fishel shared her breast cancer diagnosis this week, revealing on Monday's episode of her podcast, "Pod Meets World," that she is being treated for ductal carcinoma in situ (DCIS).
Science Daily

Study reveals short term safety of active monitoring for ductal carcinoma in situ

The first study comparing surgery to active monitoring as treatment for ductal carcinoma in situ (DCIS) finds women who carefully monitor the precancerous cells are no more likely to develop breast ...

Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer

The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the ...
Pharmabiz

ImmunityBio’s Anktiva receives Saudi FDA approval for non-muscle invasive bladder cancer with carcinoma in-situ

ImmunityBio’s Anktiva receives Saudi FDA approval for non-muscle invasive bladder cancer with carcinoma in-situ: Culver City, California Friday, January 16, 2026, 15:00 Hrs [IST ...